Table 1 Patient Characteristics.

From: Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas

  All Patients ( N =325)
Characteristics No. %
Age classes
 <18 3 0.92
 18–35 71 21.85
 36–39 51 15.69
 40–49 103 31.69
 50–59 61 18.77
 60–69 31 9.54
 ≥70 5 1.54
Sex
 Male 203 62.46
 Female 122 37.54
WHO grade classes
 Grade II 109 33.54
 Grade III 72 22.15
 Grade IV 144 44.31
TCGA classes
 Classical 74 22.77
 Mesenchymal 68 20.92
 Neural 81 24.92
 Proneural 102 31.39
Chemoradiotherapy
 Radiotherapy plus other drugs 8 2.46
 Radiotherapy plus temozolomide 78 24.00
 Radiotherapy plus unknown drug 64 19.69
 Chemotherapy with temozolomide alone 12 3.69
 Chemotherapy with unknown drug alone 14 4.31
 Radiotherapy alone 87 26.77
 No data for radiotherapy plus temozolomide 1 0.31
 Radiotherapy plus no data for chemotherapy 2 0.62
 No data for chemoradiotherapy 27 8.31
 No therapy 32 9.84
Epilepsy therapy
 Anti-epileptic 85 26.15
 No therapy 157 48.31
 No data 83 25.54